Literature DB >> 1350938

Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.

L B To1, M M Roberts, D N Haylock, P G Dyson, A L Branford, D Thorp, J Q Ho, G W Dart, N Horvath, M L Davy.   

Abstract

The haematological recovery time, infection rate and supportive care requirements of patients receiving recovery phase autologous peripheral blood stem cell transplants (APBSCT) (n = 38), autologous bone marrow transplants (autoBMT) (n = 13) and allogeneic bone marrow transplants (alloBMT) (n = 14) were compared with respect to the time post-transplant to reach 0.1, 0.5 and 2.0 x 10(9) neutrophils/l and 50 and 150 x 10(9) platelets/l, the length of hospitalization, fever and antibiotic use, the incidence of documented infection and the number of red cell and platelet transfusions. The APBSCT group had a significantly more rapid recovery of neutrophils and platelets and their supportive care requirements were significantly less than the autoBMT and the alloBMT groups. There was no difference between the latter two groups. The most significant variables contributing to the differences in haematological recovery times were the granulocyte-macrophage progenitor (CFU-GM) dose infused and, to a lesser extent, patient age. The APBSCT group received a higher CFU-GM dose of 87 +/- 12 x 10(4)/kg BW compared with 12 +/- 5 and 17 +/- 3 x 10(4)/kg BW in the autoBMT and the alloBMT groups, respectively (p = 0.0001). Patient age showed a negative correlation with the rate of recovery because the APBSCT group, which recovered faster was also older (48 +/- 2 years, compared with 33 +/- 3 and 31 +/- 2, respectively, p = 0.0001). On multivariate analysis, CFU-GM dose was the only variable to show a significant correlation with all the haematological recovery endpoints studied in these 65 patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1350938

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  31 in total

Review 1.  Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood.

Authors:  Joanne Kurtzberg; Anne Drapkin Lyerly; Jeremy Sugarman
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.

Authors:  Julie R Park; Jeffrey R Scott; Clinton F Stewart; Wendy B London; Arlene Naranjo; Victor M Santana; Peter J Shaw; Susan L Cohn; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 3.  Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review.

Authors:  K Leibundgut; A Hirt; A R Lüthy; A Tobler; H P Wagner
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

4.  Storage of noncryopreserved periphered blood stem cells for transplantation.

Authors:  G Hechler; R Weide; J Heymanns; H Köppler; K Havemann
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

Review 5.  Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

Authors:  M G Kim; N Han; E-K Lee; T Kim
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

Review 6.  G-CSF-primed BM for allogeneic SCT: revisited.

Authors:  I Pessach; I Resnick; A Shimoni; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

7.  Recommendations for managing the donation of haematopoietic stem cells from related and unrelated donors for allogeneic transplantation.

Authors:  Giuseppe Aprili; Alberto Bosi; Letizia Lombardini; Simonetta Pupella; Aurora Vassanelli
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

8.  Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.

Authors:  Barbara Skopec; Matevz Skerget; Darja Zontar; Vesna Zadnik; Samo Zver
Journal:  Wien Klin Wochenschr       Date:  2017-04-24       Impact factor: 1.704

9.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.

Authors:  Lauri Burroughs; Marco Mielcarek; Marie-Térèse Little; Gary Bridger; Ron Macfarland; Simon Fricker; Jean Labrecque; Brenda M Sandmaier; Rainer Storb
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

Review 10.  Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status.

Authors:  G Marcoullis; J Mehta; J Treleaven
Journal:  Med Oncol       Date:  1995-12       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.